UPMC Enters Into Value-Based Agreement With Biogen For Multiple Sclerosis Medications

On November 14, 2019, University of Pittsburgh Medical Center (UPMC) Health Plan announced that it entered into a value-based agreement with Biogen for multiple sclerosis (MS) medications: Tecfidera® (dimethyl fumarate) and Avonex® (interferon beta-1a). The two medications, manufactured by Biogen, are used to treat those with relapsing forms of MS. Under the agreement, Biogen will reimburse UPMC Health Plan for these medications if consumers report that the medications failed to help them. The value-based agreement went live on October 1, 2019.

The development of the value-based contract was led by the UPMC Center for Value-Based . . .